Open

Ovarian Cancer Treatment

In this study, we want to find out if a medicine called Olaparib works as well as the usual treatment for ovarian cancer. We also want to see if this medicine can help stop the cancer from growing or coming back.

Age & Gender

18 years ~ 99 years
Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

This study involves taking medicine through an IV, vital signs, and blood draws. This study also involves recombination testing on your DNA, platelet counting, and a pregnancy test.

In-person visits:
12

Phone or online visits:
12

Total length of participation:
24 months

Looking for Specific Volunteers

Able to participate:

You are newly diagnosed with Stage III or IV ovarian cancer (high grade serous or endometriod)
You have a documented variant (tumor or germline) in BRCA1 or BRCA2
You have received cytoreductive surgery
You have completed first line platinum-based therapy before study entry

Not eligible if:

You have received previous treatment with a PARP inhibitor, including olaparib, niraparib, and rucaparib
You have a history of myelodysplastic syndrome and/or acute myeloid leukemia
You have a history of allogeneic bone marrow transplant
You are pregnant or nursing
You have clinical evidence of disease progression

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Olivia Lara
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Uterine (endometrial), Ovarian)
Women's Health

IRB Number

25-0174

ClinicalTrials.gov

NCT06580314

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.